Image courtesy of Oxford Properties Group

A biomanufacturing facility nearing completion in Marlborough was acquired by Oxford Properties for $125 million through a sale-leaseback.

Specializing in vaccines and gene therapy, the 92 Crowley Drive facility is being developed by San Diego-based National Resilience as its flagship North American facility. The 120,000-square-foot complex includes manufacturing suites, office and warehouse space, Oxford announced.

Since 2021, National Resilience has raised over $1.2 billion for its biomanufacturing development pipeline. Oxford Properties Group leased the property for 30 years following the sale.

“Its proximity to our existing cGMP investments in Boston provides significant operational efficiencies,” Christie Chen, Director of Investments at Oxford, said in a statement.

Oxford Properties has a 1.4 million-square-foot cGMP portfolio at 12 North American sites, and another 1 million square feet in development.

Oxford now has five cGMP facilities in Greater Boston, including the operational 113,000-square-foot 33 New York Ave. in Framingham. Three developments include the 140,000-square-foot 159 Hayes Memorial Drive in Marlborough, the 108,000-square-foot 23 Sycamore Ave. in Medford and the 140,000-square-foot 172 Middlesex Turnpike in Bedford.

The firm also received approval in November to develop a 323,000-square-foot life science tower at 125 Lincoln St. in Boston’s Leather District.